| Methods |
Randomized, double‐blind, placebo‐controlled.
Weight loss trial. |
| Participants |
1047 patients with DM2 on oral agents. 1 year follow‐up. Mean age 56 y. Mean BMI 34.2 kg/m2. Mean weight 98 kg. 11 countries. |
| Interventions |
Rimonabant 20 mg daily (n=339). Attrition rate 32%.
Rimonabant 5 mg daily (n=358). Attrition rate 35%.
Placebo (n=348). Attrition rate 34%. |
| Outcomes |
weight loss, 5% and 10% responders, waist circ, lipid profile, glucose, A1c, insulin, blood pressure, insulin resistance |
| Notes |
Co‐interventions: 600 kcal/d deficit diet and exercise counseling |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
